(Q83427643)

22 January 2020

title

Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327131%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

placebo-controlled trial

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327131%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

3

G D Long

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327131%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

M H Jagasia

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327131%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

R Abonour

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327131%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

B J Bolwell

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327131%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

G G Laport

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327131%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

T B Shore

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327131%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

S Durrant

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327131%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

M-G Chen

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327131%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

R Lizambri

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327131%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

E K Waller

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327131%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

13 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327131%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

22 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327131%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327131%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327131%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

1350-1355

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22327131%20AND%20SRC:MED&resulttype=core&format=json

Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer

22 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.261

7 January 2021

Acute graft versus host disease

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.261

7 January 2021

Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.261

7 January 2021

Prophylaxis regimens for GVHD: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.261

7 January 2021

Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.261

7 January 2021

Palifermin for oral mucositis after intensive therapy for hematologic cancers

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.261

7 January 2021

The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.261

7 January 2021

Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.261

7 January 2021

Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.261

7 January 2021

Long-term follow-up of a phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.261

7 January 2021

Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.261

7 January 2021